Home › Upcoming votes › Azora Therapeutics, Inc. (DE)
This meeting took place on September 17, 2026. Official results not yet filed. Companies report them on Form 8-K, usually within four business days of the meeting; they will appear here once they have been read.
The deadline as the proxy statement states it: “vote must be received by 11:59 p.m. Eastern Daylight Time on September 16, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot: see the proxy statement. The items on this ballot could not be read from the filing with enough confidence to list them here. Read the proxy statement.
From Azora Therapeutics, Inc. (DE)’s Form 8-K, filed August 1, 2025, for the meeting held August 1, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Kevin Schuyler | 92% | — |
| Elect Director: Tony Goodman | 94% | — |
| 2. Ratification of the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ending Dece | 96% | Approved |
| 3. Approval, of the issuance of up to an aggregate of 6,730,376 shares of Common Stock upon the exercise of our Series B-1 Common Stock purc | 87% | Approved |
| 4. Approval, the issuance of up to an aggregate of 19,425,000 shares of Common Stock upon the exercise of our Series D Common Stock purchase | 88% | Approved |
| 5. Approval of an amendment to the Certificate of Incorporation, in substantially the form attached to the Definitive Proxy Statement as App | 86% | Approved |
| 6. Approval of an amendment to the Certificate of Incorporation, in substantially the form attached to the Definitive Proxy Statement as App | 85% | Approved |
| 7. Approval of an amendment to the Company's 2017 Equity Incentive Plan to increase the number of shares of Common Stock authorized for gran | 90% | Approved |
| 8. Approval of a proposal to adjourn the 2025 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation an | 88% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.